Scientist I, In Vitro Antibody Discovery jobs in United States
cer-icon
Apply on Employer Site
company-logo

Sanofi · 1 day ago

Scientist I, In Vitro Antibody Discovery

Sanofi is an R&D-driven, AI-powered biopharma company committed to improving people’s lives through innovative medicines and vaccines. The Scientist I role involves leading in vitro antibody discovery efforts, designing experiments, and analyzing data to support pipeline projects.

Health CareLife SciencePharmaceuticalTherapeutics
check
H1B Sponsor Likelynote

Responsibilities

Lead in vitro antibody discovery efforts for pipeline projects
Design and execute selection experiments with phage and yeast antibody display libraries
Analyze NGS data to identify antibody hits for downstream screening
Screen antibodies for binding (cell binding, ELISA, and SPR)
Bring innovative ideas and novel approaches to discovery projects

Qualification

Phage display technologyYeast display technologyNext-Generation SequencingScientific productivityOrganizational skills

Required

Ph.D. in a relevant field, or Master's degree with 5+ years of direct relevant experience
Proven hands-on experience with phage or yeast display technologies
Demonstrated track record of scientific productivity and publications
Familiarity with Next-Generation Sequencing (NGS) techniques
Strong organizational skills with the ability to manage multiple projects simultaneously

Benefits

High-quality healthcare
Prevention and wellness programs
At least 14 weeks’ gender-neutral parental leave

Company

Sanofi is a global biopharma company focused on prescription drugs, vaccines, and treatments for chronic, rare, and infectious diseases.

H1B Sponsorship

Sanofi has a track record of offering H1B sponsorships. Please note that this does not guarantee sponsorship for this specific role. Below presents additional info for your reference. (Data Powered by US Department of Labor)
Distribution of Different Job Fields Receiving Sponsorship
Represents job field similar to this job
Trends of Total Sponsorships
2025 (101)
2024 (68)
2023 (59)
2022 (78)
2021 (38)
2020 (38)

Funding

Current Stage
Public Company
Total Funding
$6.97B
Key Investors
Blackstone Life SciencesEvotec
2025-10-28Post Ipo Debt· $3B
2025-06-17Post Ipo Debt· $1.74B
2025-03-05Post Ipo Debt· $1.59B

Leadership Team

leader-logo
Paul Hudson
Chief Executive Officer
linkedin
leader-logo
Francois-Xavier Roger
Chief Financial Officer
linkedin
Company data provided by crunchbase